Status:

UNKNOWN

Development of a Non-Invasive DNA Methylation-Based Assay System for the Risk Assessment of Urothelial Carcinoma

Lead Sponsor:

National Taiwan University Hospital

Conditions:

Bladder Cancer

Eligibility:

All Genders

40-80 years

Brief Summary

Bladder cancer ranks the ninth in worldwide cancer incidence. Approximate 90% of bladder cancer is the malignancy of urothelium tissues, the urothelial cancer (UC). The mortality of bladder cancer is ...

Detailed Description

In the recent years, technologies of genomics, expression analysis and proteomics have been brought to guide the study of risk assessment and early detection of cancers. This proposed study aims to de...

Eligibility Criteria

Inclusion

  • those with histopathological-confirmed urothelial carcinoma will be included.

Exclusion

  • those were younger than 40 years old or with previous history of any other cancers will be excluded.

Key Trial Info

Start Date :

August 1 2008

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

July 1 2010

Estimated Enrollment :

82 Patients enrolled

Trial Details

Trial ID

NCT00867620

Start Date

August 1 2008

End Date

July 1 2010

Last Update

March 24 2009

Active Locations (0)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 0 (0 locations)

No Results Found

We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.

Development of a Non-Invasive DNA Methylation-Based Assay System for the Risk Assessment of Urothelial Carcinoma | DecenTrialz